Replimune (REPL) EBITDA (2017 - 2025)

Replimune has disclosed EBITDA across 9 years of filings, most recently posting -$71.9 million for Q4 2025.

• EBITDA for Q4 2025 came in at -$71.9 million, down 8.86% year-over-year; the trailing twelve-month figure through Dec 2025 was -$325.9 million (down 35.2% YoY), and the FY2025 annual result was -$261.6 million, down 11.44% from the prior year.
• EBITDA came in at -$71.9 million for Q4 2025 at Replimune, up from -$84.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$22.2 million in Q1 2021 to a low of -$90.4 million in Q2 2025.
• The 5-year median for EBITDA is -$56.1 million (2023), against an average of -$53.0 million.
• Across the five-year window, EBITDA plunged 65.67% in 2023 and grew 7.7% in 2024, its largest moves.
• Replimune's EBITDA stood at -$29.7 million in 2021, then tumbled by 40.18% to -$41.6 million in 2022, then sank by 35.82% to -$56.5 million in 2023, then decreased by 16.77% to -$66.0 million in 2024, then declined by 8.86% to -$71.9 million in 2025.
• The last three EBITDA figures came in at -$71.9 million (Q4 2025), -$84.3 million (Q3 2025), and -$90.4 million (Q2 2025), per Business Quant data.